Title
Cortisol, cytokines, and hippocampal volume interactions in the elderly

Permalink
https://escholarship.org/uc/item/3p6277m7

Journal
Frontiers in Aging Neuroscience, 6(JUL)

ISSN
1663-4365

Authors
Sudheimer, Keith D
O'Hara, Ruth
Spiegel, David
et al.

Publication Date
2014

DOI
10.3389/fnagi.2014.00153

Peer reviewed
Cortisol, cytokines, and hippocampal volume interactions in the elderly

Keith D. Sudheimer1, Ruth O’Hara1,*, David Spiegel1, Bevin Powers1, Helena C. Kraemer1, Eric Neri1, Michael Weiner2,3, Antonio Hardan1, Joachim Hallmayer1 and Firdaus S. Dhabhar1,4

1 Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA
2 Department of Radiology, University of California, San Francisco, CA, USA
3 Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA
4 Institute for Immunity, Transplantation, and Infection, Stanford University, Stanford, CA, USA

*Correspondence: Ruth O’Hara, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University, 401 Quarry Road, Stanford, CA 94304, USA
E-mail: roh@stanford.edu

INTRODUCTION
Cytokines are small proteins, which are produced by a variety of immune cells (lymphocytes, macrophages, natural killer cells etc.) and are critically important for cell signaling during when the immune system is mounting inflammatory responses to infection and cell damage. Cortisol is an adrenal glucocorticoid hormone produced in the zona fasciculate of the adrenal cortex and has a critical role in several physiological systems including acting as a anti-inflammatory agent.

Glucocorticoids and several cytokines have been associated with decreased hippocampal volumes and associated cognitive impairments. Endogenous cortisol levels have consistently been shown to predict smaller hippocampal volumes, faster hippocampal atrophy, and memory deficits (Lupien et al., 1998; O’Hara, 2007; O’Hara et al., 2007). Exogenous glucocorticoids can also adversely affect both hippocampal morphology and function during cognitive tasks (Hsu et al., 2002; de Quervain et al., 2003; Brown et al., 2004; Abercrombie et al., 2011) in humans, potentially by inhibiting neurogenesis and/or increasing the risk of cell death (Woolley et al., 1990; Sapolsky, 2000; Hsu et al., 2002). Specific cytokines e.g., IL-6, have been found to be inversely correlated with hippocampal gray matter volumes (Tanabe et al., 1997; Marsland et al., 2008) and can adversely affect hippocampal morphology during development in animal models (Kraemer and Blasey, 2004; Samuelsson et al., 2006). Both IL-1Beta and TNF-Alpha have also been shown to inhibit long-term potentiation and synaptic plasticity in the hippocampus and potentially contribute to excitotoxicity (Marques-Deak et al., 2005; Hermann et al., 2006; Pickering and O’Connor, 2007). In humans TNF-alpha single nucleotide polymorphisms predict smaller hippocampal volumes (Chapman et al., 1987; Spath-Schwalbe et al., 1998; Baune et al., 2012).

Glucocorticoids and cytokines exert their effects on the brain by acting directly on receptors and indirectly through a variety of mechanisms such as neurotransmission, intracellular signaling, and subsequent gene expression. Cortisol receptors are expressed in the hippocampus and many other cortical and subcortical regions of the humans brain (Sarrieau et al., 1986; Jonat et al., 1990; Pariante et al., 1999; Pace et al., 2007). Cortisol can penetrate the blood brain barrier in order to bind to these receptors (Woolley et al., 1990; Sapolsky, 2000; Pariante et al., 2004). Similarly, for cytokines there is evidence from both human and animal studies that IL-1, IL-6, and TNF-alpha protein and/or receptors are expressed in hippocampus (Schöbitz et al., 1994; Banks et al., 1995; Chandler et al., 1997; Vitkovic et al., 2000a,b; Quan et al., 2003; Reiche et al., 2004; Yamamoto et al., 2006;
Yirmiya and Goshen, 2011). Furthermore, microglia located throughout the brain express IL-1Beta, IL-6, IL-8, IL-10, IL-12, IL-15, and TNF-alpha as well as the IL-1R1 (receptor) (Lee et al., 2002) which interacts with IL-1Beta and is dynamically expressed in rat hippocampal neurons.

The biological actions of pro-inflammatory cytokines and glucocorticoids are not independent of each other and interact on multiple levels. Chronic exposure to glucocorticoids are known to inhibit the immune system cells responsible for producing peripheral cytokines (Dhabhar, 2009). Glucocorticoids can exert broad anti-inflammatory effects by inhibiting the transcription and action of many of the pro-inflammatory cytokines including IL-1Beta, IL-6, TNF, and others (see Webster et al., 2002 for a review). Cytokines can also exert influence over glucocorticoid secretion, bioavailability, and signaling. IL-1Beta and IL-6 can activate the HPA axis (Berkenshoch et al., 1987; Mastorakos et al., 1993; Shintani et al., 1995; Besedovsky and del Rey, 2000) directly. Pro-inflammatory cytokines that produce fever can indirectly dislodge significant amounts of biologically inactivated glucocorticoids from corticosteroid binding globulin in the blood (Cameron et al., 2010) making cortisol more available to target tissues. In addition IL-1 and TNF-Alpha can impair cortisol signaling by interfering with glucocorticoid receptor phosphorylation and interactions between the ligand-receptor complex and glucocorticoid response elements (see Pace et al., 2007 for review).

Despite many known parallels between cytokine and glucocorticoid influence on the hippocampus, and known physiological interactions between these systems, relatively few studies have systematically addressed the issue of interactions between cytokines and glucocorticoids on the level of gross hippocampal morphology. To address this gap in the literature the current study was designed to characterize the independent and interactive effects of endogenous levels of cortisol and several major cytokines (IL-1Beta, IL-6, IL-8, IL-10, IL-12, TNF-alpha), on hippocampal volume in the elderly.

METHODS AND MATERIALS

Participants included 28 community-dwelling older adults (15 females and 13 males) between 61 and 100 years of age (mean = 69.0, SD = 8.6). Participants were recruited through advertisements, contacts with local senior centers, or had previously participated in studies at Stanford University. All participants provided written informed consent for their participation in accordance with the Stanford University internal review board's regulations. All participants filled out questionnaires relating to their current medical conditions and medical history. They also underwent the Mini-Mental State Exam (MMSE) (Folstein et al., 1975) and the Structured Clinical Interview for DSM-IV-TR (SCID). Individuals with a MMSE less than 26 or with any Axis I psychiatric disorders were excluded. Participants were also excluded if they were currently using any systemic corticosteroids, psychotropic medications, short-acting anxiolytics, sedative hypnotics, or medications with significant impact on cytokine levels, cholinergic, or anticholinergic side effects, as well as any FDA-approved medications for the treatment of Alzheimer’s disease. Some participants had a prior history of high blood pressure, or other cardiovascular issues, all of which were stabilized or resolved at the time of the study. Those individuals with unresolved health issues were not included in the study.

Upon entry into the study, all participants had whole blood drawn at the Stanford University Clinical Translational Research Unit for assessment of circulating cytokine levels. Whole-blood was collected into 10 ml SST tubes (Becton Dickinson, Franklin Lakes, NJ). Serum was allowed to clot for 30 min at room temperature, then spun (1300 rpm for 15 min), frozen, and stored at −75°C for subsequent cytokine quantification. A high sensitivity multiplexed sandwich immunoenasay was used to quantify IL-1Beta, IL-6, IL-8, IL-10, IL-12, and TNF-alpha, concentrations (Mesoscale Discovery, Gaithersburg, MD). The intra-assay coefficients of variation were: IL-1Beta (2.7%), IL-6 (4.4%), IL-8 (9.8%), IL-10 (3.1%), IL-12 (7.0%), and, TNF-alpha (4.2%). The inter-assay coefficients of variation were: IL-1Beta (3.0%), IL-6 (5.5%), IL-8 (6.2%), IL-10 (4.9%), IL-12 (8.7%), and, TNF-alpha (3.0%). The sensitivity of each cytokine assay conducted was IL-1Beta (1.5 pg/ml), IL-6 (0.4 pg/ml), IL-8 (0.4 pg/ml), IL-10 (0.6 pg/ml), IL-12 (2.4 pg/ml), and, TNF-alpha (0.4 pg/ml).

Participants also completed a salivary cortisol measurement protocol over 2 consecutive days in their own home. Each participant was scheduled to obtain saliva samples at the time of waking, 30 min later, and then at 1200, 1700, and 2100 h. Each participant was instructed to collect saliva using the Salivette system (Sarstedt, Inc., Newton, NC). Participants were instructed to refrigerate each sample immediately after collection. Participants then shipped samples to the Stanford Clinical and Translational Research Unit within a week of collection. Participants were instructed not to eat, drink, smoke, brush their teeth, or use mouthwash within the 30 min before collection and not to drink alcohol during the 8–10 h prior to collecting samples or during the 2 days of collection. No physical saliva stimulants were used. Our prior work compared actual times recorded by participants at each saliva collection with a Medication Event Monitoring Units (MEMS) log and indicated that older adults were highly compliant with the protocol. Samples were stored at −80°C prior to analysis. Samples were then centrifuged and analyzed for salivary cortisol using luminescence immunnoassay (LIA) reagents provided by Immuno-Biological Laboratories, Inc. (Hamburg, Germany). Assay sensitivity was 0.015 μg/dl. Intra-assay variation on three saliva pools of the low, medium, and high controls were averaged 2.78, 10.45, and 4.79%, respectively. The mean values of the low, medium, and high controls were 0.054, 0.228, and 0.863 μg/dl. The inter-assay coefficients of variation for the low, medium, and high controls were 10.9, 10.5, and 3.5%, respectively.

All MRI scans were performed at the Palo Alto VAHCS on a General Electric Signa 1.5 Tesla clinical MRI scanner with a standard radio frequency head coil. Two high resolution anatomical scans were collected: a Proton density and T2-weighted spin-echo MRI, TR/TE1/TE2 = 5000/30/80 ms, 51 contiguous axial slices (3 mm thickness) covering the entire brain and angulated parallel to the long axis of the hippocampal formation, 0.976 × 0.976 mm² in-plane resolution (acquisition time = 17 min); and a Three-dimensional spoiled GRASS (SPGR) MRI of entire brain, TR/TE = 9/2 ms, 15° flip angle, perpendicular to the long axis.
of the hippocampus, 0.976 × 0.976 mm² in-plane resolution, 1.5 mm slice thickness, no skip (acquisition time = 7 min 27 s).

Hippocampal volume measurements were carried out using a semi-automatic, commercially available, high dimensional brain-mapping tool (Medtronic Surgical Navigation Technologies, Louisville, CO). Our group (O’Hara, 2007) and others (Hsu et al., 2002) have independently validated this method, with high levels of inter-rater reliability, comparing it with manual hippocampal tracing in patient populations and healthy participants. Manual and semi-automated volume measurements of the hippocampus generally correlated better than \( r = 0.9 \) (Hsu et al., 2002). However, the semi-automated method depends less on rater judgment and manual tracing, reducing potential rater bias. All hippocampal boundaries were visually reviewed on each brain MRI. If faulty registrations of the hippocampal boundaries were found, manual corrections were made. No MRI scans had to be discarded as a result. To adjust for differences in head size, all hippocampal volumes were normalized to total intracranial volume (TIV). TIV was identified using a mask containing the brain as identified on the T2-weighted image, as described previously (Tanabe et al., 1997). Due to inter-subject differences in brain coverage during acquisition, we standardized TIV by excluding all slices below the level of the inferior aspect of the temporal lobe from the intracranial volume measurement.

In order to test the interactions amongst cytokines, waking cortisol levels, and hippocampal volumes, we employed a multiple regression approach. For each cytokine we constructed an independent multiple regression model that included waking cortisol, age, and sex as covariates and hippocampal volume as the outcome variable. All measures were entered as continuous measures with the exception of sex. The main effects of each of the cytokines and their interaction with hippocampal volume were tested in these models. All independent variables were centered in accordance with best statistical practices (Kraemer and Blasey, 2004). Cortisol and cytokine values were also log-transformed, as these measures often have skewed distributions. After log transformation simple correlations were also used to further describe the pairwise relationships amongst cytokines, cortisol, and hippocampal volume.

We stress that this is an exploratory study aimed at identifying any potential relationships between cortisol, cytokines, and hippocampal volumes in an elderly population, in order to generate hypotheses that can be tested in independent follow up studies. The exploratory nature of our study is due to the lack of extant data to suggest which specific cytokines would be most likely to interact with cortisol on hippocampal volume.

**RESULTS**

We observed main effects of both cortisol and cytokines on hippocampal volume. High levels of IL-1Beta (\( \beta = -0.59, p = 0.026 \)) and TNF-alpha (\( \beta = -0.44, p = 0.025 \)) were associated with smaller hippocampal volumes. High levels of cortisol were associated with smaller hippocampal volumes when the effects of IL-8, IL-10, or TNF-alpha, were controlled for. However, when controlling for the other cytokines under investigation this the relationship between cortisol and hippocampal volume not achieve significance (See Table 1). A non-parametric Spearman’s rank correlation also indicated only a trend level inverse relationship between cortisol and hippocampal volume (\( r = -0.33, p = 0.083 \)).

Significant interactions between cortisol and cytokine measures were also observed. These interactions were between cortisol and both IL-6 (\( \beta = -0.42, p = 0.037 \); See Figures 1, 2) and TNF-alpha (\( \beta = -0.43, p = 0.047 \); See Figures 1, 3). Having concurrently high cytokine levels and high waking cortisol levels was associated with smaller hippocampal volumes.

**DISCUSSION**

Our results suggest elevated levels of either IL-6 or TNF-alpha in combination with elevated waking cortisol is associated with reduced hippocampal volume in healthy older participants. This data also suggests that independent of the effects of cortisol, higher levels of either IL-1Beta or TNF-alpha are also associated with lower hippocampal volumes. One outlier was identified in the TNF-alpha data (far right in Figure 3). However, significant statistical interactions were observed with or without inclusion or exclusion of this outlier.

Cortisol and cytokines are both known to affect the hippocampus and to interact with each other via central and peripheral mechanisms. Cortisol is generally an inhibitory regulator of pro-inflammatory cytokine production (IL-1Beta, TNF-alpha) and action (Marques-Deak et al., 2005; Hermann et al., 2006). Cortisol is also released in reaction to the presence of pro-inflammatory cytokines (Chapman et al., 1987; Spath-Schwalbe et al., 1998). Several cytokines (IL-1Beta, IL-2, IL-4, TNF-alpha, IFN-α) also exert indirect inhibitory influence over glucocorticoid receptor translocation and signaling (Jonat et al., 1990; Pariante et al., 1999; Pace et al., 2007). These multiple levels of physiological interactions between cytokines and cortisol suggest that there are multiple potential explanations for the statistical cortisol and cytokine interactions that we observe. Two potential mechanisms may explain our findings; (1) a dual-toxicity hypothesis and (2) a peripheral cytokine activation of cortisol hypothesis.

Under the dual-toxicity hypotheses cortisol and various cytokines could be both adversely impacting hippocampal tissues resulting in volume decreases. Under the peripheral cytokine activation of cortisol hypotheses the same results could also be explained by a peripheral interaction between cytokines and cortisol. In this scenario, immune triggers could be repeatedly activating cytokines, which then induce increases in unbound cortisol. This unbound cortisol can then cross the blood-brain barrier and affects the hippocampus as well as other HPA axis regulatory mechanisms. Repeated immune challenges and subsequent cortisol release could also be an underlying mechanism for hippocampal atrophy.

Some evidence suggests that a central dual toxicity interaction is possible. Hypercortisolemia has been shown to negatively impact neuronal function in the hippocampus in a range of animal studies. Specifically there is evidence that glucocorticoids can alter dendritic morphology, inhibit neurogenesis, and increase the risk of cell death (Woolley et al., 1990; Sapolsky, 2000).

Despite a limited ability to cross the blood brain barrier previous studies suggest that peripheral cytokines can still exert
influence on central targets. These effects may be accomplished via degradation of the blood-brain-barrier, active transport into the brain, activation of central nervous system cytokines via neural signals mediated through endothelial cells astrocytes and glial cells (Banks et al., 1995; Chandler et al., 1997; Quan et al., 2003; Reiche et al., 2004; Yirmiya and Goshen, 2011). While less is known regarding the impact of cytokines on hippocampus, pro-inflammatory cytokines acting centrally can have many deleterious effects. TNF-alpha in particular has been shown to contribute to neuronal (Barker et al., 2001; McGuire, 2003; Reiche et al., 2004; Yirmiya and Goshen, 2011).

Since unbound cortisol passes through the blood-brain-barrier with high efficiency (Pariante et al., 2004) and is known to exert effects on the hippocampus (Sapolsky, 2000), this is another way cortisol and cytokines may interact to affect hippocampal morphology/physiology.

We have outlined some potential mechanisms that could underlie the statistical interactions that we observe. However, it is important to note that our data alone is not sufficient to support any of these mechanisms. Therefore, follow up studies are needed to test the validity of these hypothesized mechanisms. Furthermore, additional brain regions outside the hippocampus could have similar relationships with cortisol and pro-inflammatory cytokines. These relationships will need to be investigated to determine if these findings are specific to the hippocampus.

The current study is not without its limitations. First, we had a small sample size which likely reduced power to detect all significant relationships. Second, our study is cross-sectional, thus the directionality of the relationships we observe is currently unknown and potentially bidirectional. Thus, with these data alone we cannot determine cause and effect relationships

Table 1 | The effects and interactions of various cytokines and cortisol levels on hippocampal volume (corrected for total intracranial volume).

| Outcome Measure | Test variable(s) | Statistic | P-value |
|-----------------|------------------|-----------|---------|
| Hippocampal volume | Omnibus | $r^2 = 0.49, F_{(5, 22)} = 4.21, N = 28$ | $p = 0.008^*$ |
|                 | TNFam | $\beta = -0.44$ | $p = 0.025^*$ |
|                 | Cortisolin | $\beta = -0.37$ | $p = 0.033^*$ |
|                 | TNFam x Cortisol$^l$ | $\beta = -0.43$ | $p = 0.047^*$ |
| Hippocampal volume | Omnibus | $r^2 = 0.62, F_{(5, 17)} = 5.46, N = 23$ | $p = 0.004^*$ |
|                 | IL-12m | $\beta = -0.59$ | $p = 0.026^*$ |
|                 | Cortisolin | $\beta = -0.25$ | $p = 0.307$ |
|                 | IL-12 x Cortisol$^l$ | $\beta = -0.41$ | $p = 0.173$ |
| Hippocampal volume | Omnibus | $r^2 = 0.46, F_{(5, 22)} = 3.73, N = 28$ | $p = 0.014^*$ |
|                 | IL-6m | $\beta = -0.01$ | $p = 0.943$ |
|                 | Cortisolin | $\beta = -0.22$ | $p = 0.217$ |
|                 | IL-6 x Cortisol$^l$ | $\beta = -0.42$ | $p = 0.037^*$ |
| Hippocampal volume | Omnibus | $r^2 = 0.40, F_{(5, 22)} = 2.92, N = 28$ | $p = 0.036^*$ |
|                 | IL-8m | $\beta = -0.02$ | $p = 0.929$ |
|                 | Cortisolin | $\beta = -0.39$ | $p = 0.039^*$ |
|                 | IL-8 x Cortisol$^l$ | $\beta = 0.29$ | $p = 0.152$ |
| Hippocampal volume | Omnibus | $r^2 = 0.43, F_{(5, 22)} = 3.26, N = 28$ | $p = 0.024^*$ |
|                 | IL-10m | $\beta = -0.33$ | $p = 0.096$ |
|                 | Cortisolin | $\beta = -0.43$ | $p = 0.025^*$ |
|                 | IL-10 x Cortisol$^l$ | $\beta = 0.29$ | $p = 0.169$ |
| Hippocampal volume | Omnibus | $r^2 = 0.38, F_{(5, 22)} = 2.68, N = 28$ | $p = 0.049^*$ |
|                 | IL-12m | $\beta = -0.24$ | $p = 0.198$ |
|                 | Cortisolin | $\beta = -0.39$ | $p = 0.051$ |
|                 | IL-12 x Cortisol$^l$ | $\beta = -0.10$ | $p = 0.628$ |

$^*$p < 0.05.

$^m$Main effects, $^l$interactions within multiple regression models are indicated for the hippocampal volume. All multiple regression models include covariates for age, sex, and cortisol. Beta estimates ($\beta$) are standardized. All multiple regression models test for the main effect the cytokine, the main effect of cortisol, and the interaction between cortisol and the cytokine on hippocampal volume.
between hippocampal volume changes, cytokines, and cortisol. Longitudinal investigations are required to best address these issue of directionality and order of causation. Third, using MRI it is not possible to distinguish between processes that result in cell death and processes that result in changes in morphology. Necrotic and apoptotic processes may underlie the hippocampal volume changes that we observe to be associated with the interactions of cortisol and cytokines. However, other cellular processes such as dendritic atrophy or other cellular morphology changes may also be responsible (Gould et al., 1990; Woolley et al., 1990; Hook et al., 2007). Fourth, while participants in this study were healthy older adults, we did not assess body mass index or other physiological measures concurrently with our measures of HPA and immune function. This could partially limit our ability to detect potential significant findings. Finally, given the absence of any studies examining the interactive effects of cytokines and cortisol levels in this population, we did not have sufficient information to identify a smaller number of cytokine measures for specifying more definitive a priori hypotheses. As such, this is an exploratory, hypothesis generating investigation, which included measures of multiple cytokines. Significance levels obtained here would not withstand Bonferroni correction. Accordingly our results should be interpreted within that context and be used to inform future hypothesis driven studies that cover a narrower scope of observation and address the limitations described here.

In summary, we provide preliminary evidence for interactions between pro-inflammatory cytokine levels, waking cortisol secretion levels, and hippocampal volumes. Specifically we found evidence that higher levels of IL-6 or TNF-alpha in conjunction with higher cortisol levels are associated with smaller hippocampal volumes. Our data suggest that the interaction between waking cortisol and pro-inflammatory cytokines may be as critical an indicator of hippocampal volume-loss as the action of any of these measures in isolation. We suggest that these interactions may be due to either a dual toxicity scenario whereby cortisol and pro-inflammatory cytokines act synergistically on the hippocampus or that cytokines, acting outside of the central nervous system, are driving up levels of unbound cortisol which penetrate the blood-brain-barrier and, over time, cause hippocampal volume changes.

REFERENCES

Abercrombie, H. C., Jahn, A. L., Davidson, R. J., Kern, S., Kirschbaum, C., and Halverson, J. (2011). Cortisol's effects on hippocampal activation in depressed patients are related to alterations in memory formation. J. Psychiatry Res. 45, 15–23. doi: 10.1016/j.jpsychires.2010.10.005
Banks, W. A., Kastin, A. J., and Broadwell, R. D. (1995). Passage of cytokines across the blood-brain barrier. *Neuroimmunomodulation* 2, 241–248. doi: 10.1159/0000729202

Barker, V., Middleton, G., Davey, E., and Davies, A. M. (2001). TNFα/4 protects neurons from stress-related damage. *Nat. Neurosci.* 4, 1194–1198. doi: 10.1038/nn755

Baune, B. T., Konrad, C., Grotegerd, D., Suslow, T., Ohrmann, P., Bauer, J., et al. (2012). Tumor necrosis factor gene variation predicts hippocampal volume in healthy individuals. *Brain. Biol.* 72, 655–662. doi: 10.1016/j.biosphys.2012.04.002

Berkenbosch, F., van Oers, J., del Rey, A., Tilders, F., and Besedovsky, H. O., and del Rey, A. (2000). The cytokine-HPA axis feedback circuit. *J. Neurosci.* 69, 94–103. doi: 10.1026/jnr.10253

Lee, Y. B., Nagai, A., and Kim, S. U. (2002). Cytokines, chemokines, and cytokine receptors in human microglia. *J. Neurosci.* 69, 94–103. doi: 10.1026/jnr.10253

Li, J., Ramenad, E. R., Peng, J., Koito, H., Volpe, J. J., and Rosenberg, P. A. (2008). Tumor necrosis factor alpha mediates lipopolysaccharide-induced microglial toxicity to developing oligodendrocytes when astrocytes are present. *J. Neurosci.* 28, 5321–5330. doi: 10.1523/JNEUROSCI.3995-07.2008

Lupien, S. J., de Leon, M., de Santi, S., Convit, A., Tarshish, C., Nair, N. P., et al. (1998). Cortisol levels during human aging predict hippocampal atrophy and memory deficits. *Nat. Neurosci.* 1, 69–73. doi: 10.1038/271

Marques-Deak, A., Cizza, G., and Sternberg, E. (2005). Brain-immune interactions and disease susceptibility. *Mol. Psychiatry* 10, 239–250. doi: 10.1038/mp.2004.163

Marsland, A. L., Giaros, P. I., Abramowitz, S. M., Manuck, S. B., and Hariri, A. R. (2008). Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. *Brain. Biol.* 64, 484–490. doi: 10.1016/j.biosphys.2008.04.016

Mastorakos, G., Chrousos, G. P., and Weber, J. S. (1993). Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. *J. Clin. Endocrinol. Metab.* 77, 1690–1694.

McGuire, S. (2001). Tumor necrosis factor α is toxic to embryonic mesencephalic dopamine neurons. *Exp. Neurol.* 169, 219–230. doi: 10.1006/exnr.2001.7688

O’Hara, R. (2007). Serotonin transporter polymorphism and stress: a view across the lifespan. *Curr. Psychiatry Rep.* 9, 173–175. doi: 10.1007/s11920-007-0014-x

O’Hara, R., Schröder, C. M., Mahadevan, R., Schatzberg, A. F., Lindley, S., Fox, S., et al. (2007). Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol. *Mol. Psychiatry* 12, 544–555. doi: 10.1038/mp.2007.91

Pace, T. W. W., Hu, F., and Miller, A. H. (2007). Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. *Brain. Behav. Immun.* 21, 9–19. doi: 10.1016/j.bbi.2006.08.009

Pariante, C. M., Pearce, B. D., Pissel, T. L., Sanchez, C. I., Po, C., Su, C., et al. (1999). The proinflammatory cytokine, interleukin-1α, reduces glucocorticoid receptor translocation and function. *Endocrinology* 140, 4359–4366.

Pariante, C. M., Thomas, S. A., Lovestone, S., Makoff, A., and Kerwin, R. W. (2004). Do antidepressants regulate how cortisol affects the brain? *Psychoneuroendocrinology* 29, 423–447. doi: 10.1016/j.psyneuen.2003.10.009

Pickering, M., and O’Connor, J. J. (2007). Pro-inflammatory cytokines and their effects in the dentate gyrus. *Prog. Brain Res.* 163, 339–354. doi: 10.1016/S0079-6132(07)00260-9

Quan, N., He, L., and Lai, W. (2003). Endothelial activation is an intermediate step for peripheral lipopolysaccharide induced activation of paraventricular nucleus. *Brain Res. Bull.* 59, 447–452. doi: 10.1016/S0361-9230(02)00951-6

Reiche, E. M. V., Nunes, S. O. V., and Morimoto, H. K. (2004). Stress, depression, the immune system, and cancer. *Lancet Oncol.* 5, 617–625. doi: 10.1016/S1470-2241(04)01597-9

Samuelsson, A. M., Jennische, E., Hansson, H. A., and Holmang, A. (2006). Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learning. *J. Physiol. Regul. Integr. Comp. Physiol.* 290, R1345–R1356. doi: 10.1122/jpr.00268.2005

Sapolsky, R. M. (2000). Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. *Arch. Gen. Psychiatry* 57, 925–935. doi: 10.1001/archpsych.57.10.925

Sarre, A., Dussaillant, M., Agid, F., Philibert, D., Agid, Y., and Rostene, W. (1986). Autoradiographic localization of glucocorticosteroid and progesterone binding sites in the human post-mortem brain. *J. Steroid Biochem.* 25, 717–721.

Soehnke, B., De Kloet, E. R., and Holsboer, F. (1994). Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. *Prog. Neurobiol.* 44, 397–432. doi: 10.1016/0301-0082(94)90034-5

Shintani, F., Nakaki, T., Kanba, S., Sato, K., Yagi, G., Shiozawa, M., et al. (1995). Involvement of interleukin-1 in immobilization stress-induced increase in plasma adrenocorticotropic hormone and in release of hypothalamic monoamines in the rat. *J. Neurosci.* 15, 1961–1970.
Sudheimer et al. Cortisol, cytokines, and hippocampal volume in the elderly

Sudheimer, K. D., O’Hara, R., Spiegel, D., Powers, B., Kraemer, H. C., Neri, E., Weiner, M., Hardan, A., Hallmayer, J., and Dhabhar, F. S. (2014). Cortisol, cytokines, and hippocampal volume interactions in the elderly. Front. Aging Neurosci. 6:153. doi: 10.3389/fnagi.2014.00153

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 02 February 2014; paper pending published: 12 March 2014; accepted: 17 June 2014; published online: 03 July 2014.

Citation: Sudheimer KD, O’Hara R, Spiegel D, Powers B, Kraemer HC, Neri E, Weiner M, Hardan A, Hallmayer J and Dhabhar FS (2014) Cortisol, cytokines, and hippocampal volume interactions in the elderly. Front. Aging Neurosci. 6:153. doi: 10.3389/fnagi.2014.00153

This article was submitted to the journal Frontiers in Aging Neuroscience. Copyright © 2014 Sudheimer, O’Hara, Spiegel, Powers, Kraemer, Neri, Weiner, Hardan, Hallmayer and Dhabhar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Spath-Schwalbe, E., Hansen, K., Schmidt, F., Schrezenmeier, H., Marshall, L., Burger, K., et al. (1998). Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J. Clin. Endocrinol. Metab. 83, 1573–1579.

Tanabe, J. L., Amend, D., Schuff, N., DiSclafani, V., Ezekiel, F., Norman, D., et al. (1997). Tissue segmentation of the brain in Alzheimer disease. AJNR Am. J. Neuroradiol. 18, 115–123.

Vitkovic, L., Bockaert, J., and Jacque, C. (2000a). “Inflammatory” Cytokines. J. Neurochem. 74, 457–471. doi: 10.1046/j.1471-4159.2000.740457.x

Vitkovic, L., Konsman, J. P., Bockaert, J., Dantzer, R., Homburger, V., and Jacque, C. (2000b). Cytokine signals propagate through the brain. Mol. Psychiatry 5, 604–615. doi: 10.1038/sj.mp.4000813

Webster, J. I., Tonelli, L., and Sternberg, E. M. (2002). Neuroendocrine regulation of immunity. Annu. Rev. Immunol. 20, 125–163. doi: 10.1146/annurev.immunol.20.082401.104914

Woolley, C. S., Gould, E., and McEwen, B. S. (1990). Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons. Brain Res. 531, 225–231. doi: 10.1016/0006-8993(90)90778-A

Yamamoto, A., Schindler, C. K., Murphy, B. M., Bellver-Estelles, C., So, N. K., Taki, W., et al. (2006). Evidence of tumor necrosis factor receptor 1 signaling in human temporal lobe epilepsy. Exp. Neurol. 202, 410–420. doi: 10.1016/j.expneurol.2006.07.003

Yirmiya, R., and Goshen, I. (2011). Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 25, 181–213. doi: 10.1016/j.bbi.2010.10.015